STUDY DESIGN AND METHODS:
This is a retrospective cohort study of adults undergoing interventional radiology procedures between January 1, 2009, and December 31, 2013. Baseline characteristics, coagulation variables, transfusion requirements, and procedural details were evaluated. Propensity-matched analyses were used to assess relationships between PLT transfusions and the outcomes of interest, including a primary outcome of periprocedural red blood cell (RBC) transfusion during the procedure or within the first 24 hours after procedure.
RESULTS:
A total of 18,204 participants met inclusion criteria, and 2060 (11.3%) had a PLT count of not more than 100 3 10 9 /L before their procedure. Of these, 203 patients (9.9) received preprocedural PLTs. There was no significant difference in RBC requirements between those receiving or not receiving preprocedural PLTs in propensity-matched analysis (odds ratio [ 
CONCLUSION:
In patients with thrombocytopenia undergoing interventional radiology procedures, preprocedural PLT transfusion was not associated with reduced periprocedural RBC requirements. These findings suggest that prophylactic PLT transfusions are not warranted in nonbleeding patients with preprocedural PLT counts exceeding 50 3 10 9 /L. Future clinical trials are needed to further define relationships between prophylactic PLT administration and bleeding complications, especially at more severe levels of thrombocytopenia or in the presence of PLT dysfunction. P atients undergoing percutaneous interventional radiology procedures often present with thrombocytopenia or other laboratory markers of impaired hemostasis. Unfortunately, there is little evidence to guide the decision to correct coagulation abnormalities preprocedurally, proceed without correction of coagulation derangements, or postpone or cancel a scheduled procedure. 1 Each of these management strategies has unique and important considerations, including transfusion-related risks as well as the financial implications associated with procedural delays or potentially unnecessary transfusion therapies in patients transfused preprocedurally. Alternatively, concerns frequently arise over the withholding of potentially life-sustaining therapies associated with procedural cancellation or increased risk of procedural bleeding in those without preoperative platelet (PLT) transfusion. In the case of thrombocytopenia, PLT transfusion is commonly employed before invasive procedures. 2 While 
MATERIALS AND METHODS
This is a retrospective study conducted at the Mayo Clinic in Rochester, Minnesota, under approval of the institutional review board. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines were used in the design and conduct of this study. 3 
Study population
Inclusion criteria for this investigation consisted of patients at least 18 years of age undergoing percutaneous invasive image-guided interventions (i.e., procedures performed by the Division of Vascular/Interventional Radiology) at a single tertiary care center between January 1, 2009, and December 31, 2013, and the presence of a PLT count in the 30-day interval preceding the procedure. Exclusion criteria included lack of valid research authorization and prior inclusion in the study (no patient was included twice). For those with multiple interventional procedures during the study time frame, only the first procedure with a valid PLT count was included.
Outcome variables
The primary outcome for this study was the presence of a periprocedural RBC transfusion, defined as an RBC transfusion episode with initiation time occurring during the procedural encounter or within 24 hours after discharge from the procedural environment. RBC transfusions initiated before entering the procedure suite were not included in the outcome evaluation. Additional secondary outcomes included unanticipated return to the procedural suite or transfer to an operating room within 24 hours of the index procedure, postprocedural intensive care unit (ICU) admission and length of stay, postprocedural mechanical ventilation and duration, hospital length of stay, and all-cause hospital mortality. As a post hoc analysis, we also included the presence of a periprocedural PLT transfusion, defined as PLTs administered during the procedural encounter or in the first 24 hours after discharge from the procedural environment.
Predictor variables
The primary predictor variable for this investigation was the presence or absence of preprocedural PLT transfusion, which was defined as PLTs administered after the qualifying preprocedural PLT count and within 7 days of the procedure. For patients with multiple preprocedural PLT counts, the value closest to the time of the procedure was utilized as the qualifying PLT count. PLT transfusions preceding measurement of the qualifying PLT count were not included. Moreover, intraoperative and postprocedural PLT transfusions were not considered as predictor variables as our aim was to specifically investigate the impact of preprocedural PLT administration. Additionally, this exclusion of PLT administration after the start of the procedure avoids the potential for cause-effect inversion with the outcomes of interest. To further ensure against causeeffect inversion, the timing of PLT transfusion was defined as the actual transfusion initiation time as documented in the electronic health record rather than the time of issue from the blood bank. The presence and timing of all periprocedural transfusion episodes were extracted from the electronic health record. Patient demographics, baseline clinical characteristics, and procedural-and anesthesiarelated details were also extracted from the electronic medical record. Procedures were classified based upon bleeding risk as identified by the Consensus Guidelines for Periprocedural Management of Coagulation Status and Hemostasis Risk in Percutaneous Image-guided Interventions into low-, moderate-, or high-risk categories (Table 1) . 1 
Data sources
Assuming a periprocedural RBC transfusion event rate of 15% in the target study population (preprocedural PLT count 100 3 10 9 /L, based on historical data from the participating institution) and a prophylactic PLT transfusion rate of 10% in those with a preprocedural PLT count of not more than 100 3 10 9 /L (estimated to be 10% of the total population with qualifying PLT values), the sample size required to identify an odds ratio (OR) of 0.5 in those who receive a preprocedural PLT transfusion compared to those who do not was estimated to be 1998 total study participants (two-sided a of 0.05, b 5 0.20). Furthermore, assuming that 80% of patients would have a qualifying PLT count within 30 days of the procedure, we estimated the need to evaluate approximately 24,000 unique participants having undergone the procedures of interest.
Screening for potential study participants was performed using the OR Datamart, an institutional resource that captures clinical and procedural data for all patients who are admitted to an acute care environment including procedural suites, operating rooms, ICUs, and progressive care units at the study's participating institution. 4 This robust data warehouse also contains information on baseline demographics and clinical characteristics, fluid and transfusion therapies, periprocedural medications and laboratory values, postprocedural outcomes, and lengths of stay. Additional baseline characteristics pertinent were obtained from a second validated database, the Mayo Clinic Life Sciences System (MCLSS). 5 Both databases have undergone extensive validation with accuracy superior to manual data collection alone. 6 
Statistical considerations
Baseline demographics, clinical characteristics, and procedure-related information were summarized and presented as median (25%-75% interquartile range [IQR]) for continuous data elements and frequencies (%) for categorical data, respectively. A PLT count of not more than 100 3 10 9 /L was used as a threshold for thrombocytopenia in this study for two reasons: 1) recent evidence from surgical populations has shown increased rates of bleeding complications with preoperative PLT counts of not more than 100 3 10 /L as a transfusion trigger for PLT therapy and that transfusion strategies may vary significantly by practice location, sensitivity analyses using PLT counts of not more than 75 3 10 9 /L and of not more than 50 3 10 9 /L were planned a priori. 1, 9 The relationships between prophylactic preprocedural PLT transfusion and bleeding complications were explored with both univariate and multivariable analyses. As observational studies risk unequal distributions of key confounding variables due to the lack of subject randomization, propensity-matched analyses were performed. Logistic regression was used to calculate propensity scores utilizing all hypothesized confounding variables (variables included in the propensity score estimation are included in Fig. 2 ). Each patient who received preprocedural PLT transfusion was matched with up to two patients who did not receive preprocedural PLT transfusion, using exact matching on procedure bleeding risk (low, moderate, high) and optimal matching on propensity score (60.10). 10 Standardized mean differences after matching adjustment as well as p values from conditional logistic regression analysis using matched sets as strata were obtained for each covariate to assess the effectiveness of the matching to control for confounding of the observed variables. Logistic regression was then used to assess whether the likelihood of receiving periprocedural RBC transfusion is associated with preprocedural exposure to prophylactic PLT transfusion. Similar procedures were carried out for the secondary outcomes as well. Multiple additional sensitivity analyses were planned a priori: 1) restriction to study participants undergoing low-, moderate-, or high-risk procedure, respectively; 2) restriction to patients undergoing emergency procedures; and 3) restriction to patients with PLT counts of not more than 75 3 10 9 /L and of not more than 50 3 10 9 /L. In addition, recognizing that some preprocedural PLT transfusions may occur in the setting of ongoing resuscitation from hemorrhage, patients receiving RBC transfusion within 24 hours of the procedure were excluded. All statistical analyses were performed with statistical software (JMP base Version 9.0.1 and SAS 9.1.4, SAS Institute, Inc.).
RESULTS
A total of 42,952 invasive image-guided interventions were performed on 24,626 unique patients aged 18 years or greater. Among the 21,394 patients with a qualifying preprocedural PLT count, 2060 (9.6%) had a PLT count of not more than 100 3 10 9 /L at the time of needle placement (Fig. 1 ). Of these, 203 patients (9.9%) were administered PLTs for the correction of preprocedural thrombocytopenia before entry into the procedural suite. The median (IQR) time between PLT count measurement and procedure onset was 8.5 (4.1-22.1) hours. In those who received a preprocedural PLT transfusion as defined by the study protocol, the median time from initiation of the last qualifying PLT component to the onset of the procedure was 1.8 (0.9-3.6) hours. Comparison of baseline clinical, demographic, and procedural characteristics for those with a PLT count of not more than 100 3 10 9 /L are displayed in Table 2 , with key differences including a higher rate of hematologic malignancies, lower baseline PLT counts and hemoglobin (Hb) values, an increased incidence of emergency procedures, and a higher rate of procedures performed under general anesthesia in those receiving PLT transfusions. Conversely, those receiving PLTs were less likely to be receiving aspirin, nonsteroidal antiinflammatory drugs (NSAIDs), or warfarin in the perioperative period. In addition, the incidence of diabetes, congestive heart failure, and chronic renal failure were lower in the PLT-transfused group.
Results of unadjusted analyses evaluating the associations between preprocedural PLT transfusions with patient outcomes are displayed in Table 3 . The frequency of periprocedural RBC transfusion among those who received preprocedural PLT transfusion versus those who did not was 28% versus 12% (p < 0.001). In addition, those receiving PLTs had a higher rate of ICU admission (36% vs. 24%, p < 0. and increased rates of periprocedural PLT transfusion (23% vs. 7%, p < 0.001).
A total of 2012 of the study subjects were assigned a propensity score; 48 (2.3%) were not assigned a score as a result of missing data, of whom five had received a preprocedural PLT transfusion. The standardized differences of propensity scores in the cohort of patients who did and who did not receive preprocedural PLTs are shown in Fig.  2 . From those with available propensity scores, 179 study subjects receiving preprocedural PLT transfusion were propensity matched to 342 study subjects who did not. Sixteen subjects who received PLTs were matched to a single nontransfused subject and 163 subjects were matched to two nontransfused subjects. A total of 19 subjects who had received PLTs were removed from the propensitymatched analyses due to the lack of a suitable nontransfused propensity-matched study subject. Propensity matching was effective in reducing baseline covariate imbalances between PLT exposure groups (Table 2, Fig. 2 ).
In the propensity-matched cohort, 48 (27%) of the PLT-transfused subjects received a periprocedural RBC transfusion compared with 69 (20%) of those who did not receive preprocedural PLTs. This difference was not statistically significant (OR [95% CI], 1.45 [0.95-2.21]; p 5 0.085). Preoperative PLT transfusion was associated with increased ICU admission rates (36% vs. 27%; OR [95% CI], 1.57 [1.07-2.32]; p 5 0.022). There were no significant differences in hospital length of stay, postprocedural mechanical ventilation rates, periprocedural PLT transfusion requirements, or mortality between PLTtransfused and nontransfused groups. The results of sensitivity analyses assigned a priori are displayed in Table 5 . Notably, there was no difference in RBC transfusion rates using lower PLT count thresholds of 50 3 10 9 and 75 3 10 9 /L.
DISCUSSION
This investigation was performed to assess the relationships between preprocedural PLT transfusion and periprocedural bleeding complications in patients with thrombocytopenia undergoing interventional radiology procedures. To that end, there was no evidence for decreased periprocedural RBC requirements or improved clinical outcomes with preprocedural PLT transfusion. The frequency of PLT transfusions has increased in recent years, with the majority of transfusions being given prophylactically for the prevention of bleeding. 2, 11, 12 However, the appropriate PLT count threshold for prophylactic transfusion and the utility of such transfusions to mitigate bleeding complications remains unclear. This is particularly relevant for patients undergoing interventional procedures in which there are limited data available to make evidence-based decisions. In a prospective cohort study of 105 patients with thrombocytopenia undergoing central venous catheter placement, there was no significant differences in bleeding, infection, thrombosis, or mortality between those receiving or not receiving prophylactic PLT transfusion. 13 In 55 patients with thrombocytopenic thrombotic purpura undergoing central venous catheter placement for plasma exchange, bleeding and mortality rates were increased in those receiving preprocedural PLT transfusions, although transfused patients were more acutely ill. 14 An additional observational study of nearly 400 patients with PLT counts between 50 3 10 9 and 99 3 10 9 /L and mild coagulopathy undergoing paracentesis or thoracentesis without prophylactic transfusion of PLTs found no bleeding complications, suggesting that these procedures are likely safe even in the presence of abnormal laboratory markers of hemostasis. Moreover, in patients undergoing percutaneous liver biopsy, periprocedural bleeding complications do not correlate with preprocedural PLT count, 15, 16 and procedures such as marrow biopsy and lumbar puncture are routinely performed with PLT counts well below 50 3 10 9 /L with a very low incidence of hemorrhagic complications. [17] [18] [19] Hence, although guidelines continue to focus on preprocedural PLT counts for the assessment of bleeding risk, there is little evidence to support a relationship between PLT quantity and bleeding complications. In this investigation, patients transfused prophylactically with PLTs had no significant reduction in subsequent RBC transfusion requirements. In fact, there was a trend toward increased RBC requirements after PLT administration, which may be related in part to unique provider transfusion practices. For example, a provider inclined to transfuse PLTs before needle placement may also be more inclined to transfuse RBCs in the periprocedural period. Additionally, it is possible that PLT transfusion was indicative of a sicker patient population, despite our efforts at careful propensity adjustment. Although not a highvolume product, PLT transfusion may also contribute to hemodilution, which may decrease Hb concentration beyond transfusion thresholds. Interestingly, PLT administration was associated with increased ICU admission rates, which may also be a reflection of provider preference for higher levels of postoperative care in transfused patients or residual unmeasured confounding. Nevertheless, clinical outcomes were not superior in any of the analyzed categories for those receiving preprocedural PLTs, suggesting that at a minimum, prophylactic PLT transfusion does little to improve patient outcomes. Similar results have recently been shown in patients with thrombocytopenia undergoing noncardiac surgery. There are several important limitations for the present investigation, most notably the retrospective design of this investigation with potential for residual confounding and bias. Propensity matching was effective in reducing between group differences, although several variables remained with absolute standardized differences greater than 0.1 including the rate of general anesthesia, which was slightly higher in those receiving PLTs and the rates of low-molecular-weight heparin and warfarin use which were marginally greater in those not receiving PLT therapy. Hence, despite careful statistical adjustments with propensity matching, it is possible that the lack of perceived benefit after PLT transfusion may be confounded by a sicker patient population in those receiving PLTs. In addition, it should be noted that the precise clinical circumstances affecting the decision to transfuse or withhold transfusion in the periprocedural period was unable to be directly assessed. RBC transfusion was used as a surrogate for clinical bleeding; however, transfusion may have occurred for other causes (e.g., anemia of chronic disease). In addition, some clinically significant bleeding complications (e.g., spinal hematoma, pseudoaneurysm formation) may not have been captured by the primary outcome measure if they were not severe enough to warrant RBC transfusion. As mentioned previously, PLT transfusions occurring after entry into the procedural suite were excluded as predictor variables in an attempt to minimize the probability for cause-effect inversion with the primary outcome (e.g., PLTs given to prevent bleeding versus PLTs given in response to ongoing hemorrhage). This may have excluded some prophylactic transfusions from analysis. As a post hoc analysis, however, we did include periprocedural PLT transfusions as a surrogate marker for bleeding complications. There were no differences between propensity-matched groups. Furthermore, it must be noted that any observed relationships between prophylactic transfusion and the outcomes of interest represent associations without any inference of causality. Finally, this investigation represents the experience of a single tertiary care medical center. Study results will ultimately require external validation in a multicenter prospective investigation or randomized clinical trial.
In conclusion, thrombocytopenia is commonly encountered in patients undergoing percutaneous interventional procedures. In this investigation, there was no improvement in bleeding complications or clinical outcomes when preprocedural PLT transfusions were provided for PLT counts exceeding 50 3 10
